Teva up on better-than-expected financials

13 February 2017

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) posted fourth-quarter and full-year 2016 results that beat expectations, sending the firm’s shares up 4.5% to $33.65 in pre-market trading this morning.

Sales for the fourth quarter increased 33 to $6.5 billion, compared with analysts’ forecast of $6.24 billion, primarily due to the inclusion of $630 million from the Actavis Generics acquisition. Global sales of its best-selling branded multiple sclerosis drug Copaxone (glatiramer acetate) rose 6% in the quarter to $1.0 billion.

Earnings per share were $1.38 excluding one-time items in the quarter, up from $1.28, beating the expectations of $1.35 on revenue of $6.24 billion, according to Thomson Reuters. Generally accepted accounting principles (GAAP) gross product was $3.4 billion in the fourth quarter of 2016, up 19% compared to the fourth quarter of 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK